Cure My Disease

Don't miss your cure!

 Log in / Sign up

A single blood test may reveal whether a gene tied to transplant outcomes influences psoriatic arthritis risk.

NCT ID NCT07718815

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study compares the prevalence of the HLA B leader gene in 658 people with psoriatic arthritis and a healthy control group. Researchers will also look at the related HLA B27 gene. The goal is to see whether this genetic marker, already known to affect outcomes in bone marrow transplants, is more common in people with psoriatic arthritis. Participants provide one extra blood sample for genetic testing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood test for genetic analysis
What this could lead to
If a link is found, the HLA B leader gene could become a new target for understanding or treating psoriatic arthritis.
What could go wrong
This is an observational study, not a treatment trial. It may find no meaningful difference between groups, and even if it does, the practical implications are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 658 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For the "Patient" group: * Patient over 18 years of age * Patient affiliated to a social security scheme * Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie. * For the "control" group: * Individuals over 18 years of age * Individual affiliated to a social security scheme * Individual having agreed to participate in the study * Individuals with no inflammatory or autoimmune diseases Exclusion Criteria: * Patient or control not understanding French * Patient not included in the Amiens Picardie University Hospital's "Psoriatic Rheumatism" cohort, or control not included in the Amiens Picardie University Hospital's bone marrow donor cohort. * Patient or control objecting to participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HLA B leader are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HLA B leader HLA B27 Psoriatic arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Amiens Picardie

    RECRUITING

    Amiens, Picardie, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.